Specifically, MS plays its antiallergic role through the activation of the IL-10 pathway via CD4+ CD25+ Foxp3+ augmentation and p38 MAPK and NF-κB attenuation, antagonized by the anti-CD25 antibody. This evidence concerns the gene CD4 and myeloid sarcoma.